Navigation Links
Mederi Therapeutics Announces Receipt of FDA 510(k) Clearance for the MDRF1 Radiofrequency Generator
Date:1/31/2011

GREENWICH, Conn., Jan. 31, 2011 /PRNewswire/ -- Mederi Therapeutics Inc. announced today that it has received FDA 510(k) clearance for its new MDRF1 Generator.

The Mederi RF Generator powers the Stretta® System for treatment of Gastroesophageal Reflux Disease (GERD) as well as the Secca® System for Bowel Incontinence or Bowel Control Disorder (BCD).

"Today's FDA clearance of the MDRF1 is the culmination of significant investment and design efforts by Mederi. The goal of the MDRF1 project was to produce a system of the highest quality and reliability to treat these two serious and debilitating conditions," stated Will Rutan, Mederi's CEO. "Mederi's new RF generator dramatically reduces the user's capital spending requirements by combining two power generators into one. The MDRF1 is a smaller, lighter and highly portable radiofrequency generator with a more intuitive user interface than its predecessors," continued Rutan.  "The MDRF1 combines the functionality of these earlier models into one system that powers both the Stretta and Secca devices."

The availability of these products represents a significant advancement in minimally invasive options for the millions of people who suffer from GERD or BCD. The treatments involve delivery of radiofrequency energy to the sphincter muscles at either end of the digestive system. Both Secca and Stretta bridge the gap between conservative or pharmacologic therapy and invasive surgery – giving doctors and patients an effective and less complicated alternative.

This FDA 510(k) clearance, as well as our recently awarded CE Mark, and ISO 13485 certification, demonstrate Mederi's steadfast commitment to innovation, safety and quality.

Additional information is available at www.mederitherapeutics.com.

ABOUT MEDERI

Mederi Therapeutics manufactures and markets innovative medical devices that deliver radiofrequency energy to treat disease states affecting the human digestive system. All Mederi therapies are outpatient, minimally invasive, and promote rapid recovery. Mederi Therapeutics is located in Greenwich, Connecticut.

Contact: Sheila Doyle, Manager of Communications and Marketing

203 930 9980


'/>"/>
SOURCE Mederi Therapeutics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Mederi Therapeutics Announces Receipt of CE Mark for its Second Generation Secca® and Stretta® Systems
2. Interleukin (IL)-12 Secretion Can Predict Potency of Argos Therapeutics Arcelis™ Dendritic Cell (DC) Immunotherapy and Can Be Used as Potency Marker in Phase 3 Clinical Trial
3. Pervasis Therapeutics to Develop Novel Cell-Based Approach to Target Tumor Environment, Prevent Cancer Recurrence
4. PTC Therapeutics President and CEO Elected AAAS Fellow
5. Resolvyx Pharmaceuticals and Celtic Therapeutics Enter Final Agreement in Ophthalmology
6. ADVENTRX Announces Signing of Term Sheet for Acquisition of Poloxamer-Based Therapeutics
7. Echo Therapeutics to Present at the OneMedForum 2011 Conference
8. Esperion Therapeutics Initiates Phase 2 Clinical Study for ETC-1002
9. Altheus Therapeutics Completes Phase I Clinical Study of Zoenasa™ in Ulcerative Colitis
10. Echo Therapeutics Receives Funding and Commitment of Approximately $5.5 Million
11. Alpha-1 Foundation Awards Two Research Grants with Support from Talecris Biotherapeutics, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... , April 27, 2016 ... accelerator (MR-linac) platform will be the focal point of ... of the European Society for Radiotherapy & Oncology, taking ... MR-linac integrates a state-of-the-art radiotherapy system and a high-field ... to clearly see the patient,s anatomy in real time. ...
(Date:4/27/2016)... -- Shire plc (LSE: SHP, NASDAQ: ... Officer, will present at the Deutsche Bank 41st Annual Health ... Wednesday, May 04, 2016, 10:00 am EDT (15:00 BST). ... Presentations and Webcasts section of Shire,s Investor website at ... available on this same website for approximately 90 days. ...
(Date:4/27/2016)... At the Sachs CEO forum ... Phase 2 clinical study of its lead drug candidate, ... implantation (CI) surgery. This large, placebo-controlled, double-blind, phase 2 ... and France . STR001 ... time of surgery. "Despite advances in cochlear implant technology, ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... 2016 , ... Mercy College is expanding its Graduate Business Programs to the ... due to high demand: Master of Business Administration (MBA), Master of Organizational Leadership (MSOL) ... , School of Business Graduate Program Chair Dr. Ray Manganelli said: “We believe that ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... , announces the addition Onnit brand Alpha BRAIN and New Mood Daily-Stress Formula ... brain and mood optimization products to the store is just one more way ...
(Date:4/29/2016)... ... April 29, 2016 , ... Dr. Bernie Siegel, ... "LOVE, MEDICINE and MIRACLES") addresses touchy topics related to Death live on ... Dr. Bernie Siegel, author of a plethora of essential books-to-read for physicians ...
(Date:4/29/2016)... Petersburg, Fla. (PRWEB) , ... April 29, 2016 ... ... Children’s Hospital surgeon reveals that infants born with severe congenital diaphragmatic hernia have ... babies is born with congenital diaphragmatic hernia (CDH)—a condition where the diaphragm fails ...
(Date:4/29/2016)... York, NY (PRWEB) , ... April 29, 2016 ... ... manufacturer and engineer of patented products, announces the Gyrociser, an exercise invention which ... is worth $2 billion," says Scott Cooper, CEO and Creative Director of World ...
Breaking Medicine News(10 mins):